Absence of Neuropsychologic Deficits in Patients Receiving Long-Term Treatment With Alprazolam-XR for Panic Disorder

No abstract is available for this paper.

• Publication year

  2001

• Venue

  Journal of Clinical Psychopharmacology

• Publication date

  2001-04-01

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.1097/00004714-200104000-00003PMID 11270908
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Influence of dosing regimen on alprazolam and metabolite serum concentrations and tolerance to sedative and psychomotor effects

  2005cited by this paper
• Chronic use of benzodiazepines and psychomotor and cognitive test performance

  2004cited by this paper
• Pharmacokinetics and pharmacodynamics of alprazolam after oral and IV administration

  2004cited by this paper
• Psychomotor performance of long-term benzodiazepine users before, during, and after benzodiazepine discontinuation.

  1999cited by this paper
• A neuropsychological study of panic disorder: negative findings.

  1998cited by this paper
• Pharmacokinetics and Psychomotor Performance of Alprazolam: Concentration—Effect Relationship

  1997cited by this paper
• Neuropsychological changes during steady‐state drug use, withdrawal and abstinence in primary benzodiazepine‐dependent patients

  1995cited by this paper
• Comparison of acute alprazolam (0.25, 0.50 and 1.0 mg) effects versus those of lorazepam 2 mg and placebo on memory in healthy volunteers using laboratory and telephone tests

  1995cited by this paper
• Memory functions, alprazolam and exposure therapy: a controlled longitudinal study of agoraphobia with panic disorder

  1994cited by this paper
• A double-blind, placebo-controlled, multicenter study with alprazolam and extended-release alprazolam in the treatment of panic disorder.

  1994cited by this paper
• Lack of cognitive recovery following withdrawal from long-term benzodiazepine use

  1994cited by this paper
• Double-blind, placebo-controlled study of a once-a-day, sustained-release preparation of alprazolam for the treatment of panic disorder.

  1993cited by this paper
• Clinical Pharmacokinetics of Alprazolam

  1993cited by this paper
• Maintenance drug treatment of panic disorder. I. Results of a prospective, placebo-controlled comparison of alprazolam and imipramine.

  1993cited by this paper
• Psychological treatment of panic: work in progress on outcome, active ingredients, and follow-up.

  1993cited by this paper
• Group cognitive-behavioral treatment of panic disorder.

  1993cited by this paper
• Plasma alprazolam concentrations. Relation to efficacy and side effects in the treatment of panic disorder.

  1993cited by this paper
• Componential analysis of problem-solving ability: performance of patients with frontal lobe damage and amnesic patients on a new sorting test.

  1992cited by this paper
• Alpidem and Lorazepam in the Treatment of Patients with Anxiety Disorders: Comparison of Physiological and Psychological Effects

  1992cited by this paper
• Adverse effects of benzodiazepines.

  1991cited by this paper
• Pharmacokinetics and Pharmacodynamics of Alprazolam Following Single and Multiple Oral Doses of a Sustained‐Release Formulation

  1989cited by this paper
• Cognitive impairment in long-term benzodiazepine users

  1988cited by this paper
• Performance effects of diazepam during and after prolonged administration

  1986cited by this paper
• Tranquillising memories: a review of the effects of benzodiazepines on human memory.

  1986cited by this paper
• Memory for verbal and nonverbal stimuli in learning disability subgroups: analysis by selective reminding.

  1985cited by this paper
• Effects of chronic benzodiazepine administration on neuropsychological performance.

  1985cited by this paper
• The amnesic action of benzodiazepines in man.

  1985cited by this paper
• Effects of chronic benzodiazepine administration on neuropsychological performance.

  1985cited by this paper
• Behavioral effects of diazepam and propranolol in patients with panic disorder and agoraphobia.

  1984cited by this paper
• Validity of the Trail Making Test as an Indicator of Organic Brain Damage

  1958cited by this paper

• Characterization of Extended-Release Lorazepam

  2023cites this paper
• The effect of second-generation antidepressant treatment on the attention and mental processing speed of patients with major depressive disorder: A meta-analysis study with structural equation models.

  2022cites this paper
• Co-occurring OCD and Panic Disorder: A Review of Their Etiology and Treatment.

  2022cites this paper
• THE EFFECT OF SECOND-GENERATION ANTIDEPRESSANT TREATMENT ON THE EXECUTIVE FUNCTIONS OF PATIENTS WITH MAJOR DEPRESSIVE DISORDER: A META-ANALYSIS STUDY WITH STRUCTURAL EQUATION MODELS.

  2020cites this paper
• Absence of definitive scientific evidence that benzodiazepines could hinder the efficacy of exposure‐based interventions in adults with anxiety or posttraumatic stress disorders: A systematic review of randomized clinical trials

  2020cites this paper
• Insomnia and Dysautonomia with Contactin-Associated Protein 2 and Leucine-Rich Glioma Inactivated Protein 1 Antibodies: A “Forme Fruste” of Morvan Syndrome?

  2019cites this paper
• [Sleep disturbances in panic disorders].

  2018cites this paper
• The Black Book of Psychotropic Dosing and Monitoring.

  2018cites this paper
• S3-Leitlinie Angststörungen

  2015cites this paper
• Combination Psychological and Pharmacological Treatments for Panic Disorder

  2014cites this paper
• Immediate and delayed visual memory and recognition in patients with panic disorders.

  2013cites this paper
• The basic pharmacoepidemiology of benzodiazepine use in Norway 2004-9.

  2011cites this paper
• Efectos cognitivos del consumo prolongado de alprazolam: el síndrome amnésico

  2011cites this paper
• Neuropsychologie der Angststörungen

  2010cites this paper
• Klinisch-Neuropsychologische Aspekte der Therapie mit Psychopharmaka

  2010cites this paper
• Benzodiazepines: good or bad medicine?

  2010cites this paper
• Benzodiazépines: médicaments honnis ou bénis?

  2010cites this paper
• Is it Beneficial to Add Pharmacotherapy to Cognitive-Behavioral Therapy when Treating Anxiety Disorders? A Meta-Analytic Review.

  2009cites this paper
• Combined psychotherapy plus benzodiazepines for panic disorder.

  2009cites this paper
• How to grade categories of evidence

  2008cites this paper
• Are neuropsychological deficits trait markers in OCD?

  2008cites this paper
• Clinical-psychophysiological studies of patients with panic attacks with and without agoraphobic disorders

  2008cites this paper
• [Clinical and psychophysiological study of patients with panic attacks with or without agoraphobic disorders].

  2007cites this paper
• Brain bioelectrical activity at a high anxiety level in humans

  2007cites this paper
• Preliminary communication Differential performance on tasks of affective processing and decision-making in patients with Panic Disorder and Panic Disorder with comorbid Major Depressive Disorder

  2006cites this paper
• Differential performance on tasks of affective processing and decision-making in patients with Panic Disorder and Panic Disorder with comorbid Major Depressive Disorder.

  2006cites this paper
• Clinical pharmacology, clinical efficacy, and behavioral toxicity of alprazolam: a review of the literature.

  2006cites this paper
• A meta-analysis of the efficacy of psycho- and pharmacotherapy in panic disorder with and without agoraphobia.

  2005cites this paper
• Developments in treatment of anxiety disorders: Psychotherapy, pharmacotherapy, and psychosurgery

  2004cites this paper
• Benzodiazepine Use Associated with Decreased Memory for Psychoeducation Material in Cognitive Behavioral Therapy for Panic Disorder

  2004cites this paper
• Alprazolam extended-release in panic disorder

  2004cites this paper
• A review of drug use and driving: epidemiology, impairment, risk factors and risk perceptions.

  2004cites this paper
• Neuropsychologische Aspekte der Therapie mit Psychopharmaka

  2004cites this paper
• Clinical Pharmacology, Clinical Efficacy, and Behavioral Toxicity of Alprazolam: A Review of the Literature

  2004cites this paper
• Benzodiazepine discontinuation treatment in outpatients with complicated dependence

  2003cites this paper
• World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Post-Traumatic Stress Disorders – First Revision

  2002cites this paper
• ALPRAZOLAM: profilo farmacoeconomico nei disturbi d’ansia e da attacchi di panico

  2002cites this paper